A Phase 3 clinical trial involving thymosin beta-4 has been updated to completed status as of August 28, 2026. The trial, registered as NCT03937882 and titled "Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3," evaluated RGN-259, an ophthalmic solution formulation containing thymosin beta-4, in patients with dry eye syndrome.
The study is classified under ClinicalTrials.gov as Phase 3 and its current status is listed as COMPLETED. This designation reflects the trial's progression through its planned phases and completion of its protocol, according to the registry entry. No results, efficacy data, or safety outcomes are included in this status update.
Thymosin beta-4 remains classified as an unapproved compound under active research. It has not received regulatory approval for the indication studied in this trial or for any other clinical use. The completion of ARISE-3 represents a milestone in the clinical development timeline for RGN-259 but does not by itself indicate any conclusion regarding the compound's safety or effectiveness.
Readers interested in additional background on thymosin beta-4, including its research history and current regulatory status, can consult the compound overview for further context.